

# Dana V Ferraris

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/378704/dana-v-ferraris-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11  
papers

500  
citations

8  
h-index

13  
g-index

13  
ext. papers

616  
ext. citations

5.6  
avg, IF

4.34  
L-index

| #  | Paper   | IF  | Citations |
|----|---|-----|-----------|
| 11 | Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). <i>Expert Opinion on Therapeutic Patents</i> , <b>2021</b> , 31, 609-623  | 6.8 | 5         |
| 10 | Integrating DNA-encoded chemical libraries with virtual combinatorial library screening: Optimizing a PARP10 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2020</b> , 30, 127464  | 2.9 | 5         |
| 9  | Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics. <i>Molecules</i> , <b>2019</b> , 24,  | 4.8 | 7         |
| 8  | The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007756  | 7.6 | 93        |
| 7  | Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2018</b> , 28, 2050-2054  | 2.9 | 24        |
| 6  | Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2017</b> , 27, 6-10 | 2.9 | 8         |
| 5  | Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 8621-33   | 8.3 | 53        |
| 4  | D-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2016</b> , 26, 2088-91  | 2.9 | 8         |
| 3  | Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA). <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 2810-9   | 8.3 | 19        |
| 2  | Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 4539-50   | 8.3 | 11        |
| 1  | Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. <i>Journal of Medicinal Chemistry</i> , <b>2010</b> , 53, 4561-84   | 8.3 | 267       |